Publication of 2022 EORTC Annual Report
25 May 2023
This comprehensive report collects the most relevant and up-to-date information on EORTC’s activities demonstrating the continuous progress achieved in the field of clinical cancer research by our organisation.
The 2022 edition is a very special one, as last year marked a significant milestone for our organisation which celebrated its 60th anniversary. Today, EORTC is a well-renowned independent, academic and multidisciplinary clinical cancer research organisation, whose network encompasses over 3,400 collaborators from diverse disciplines across more than 50 countries. 22,000 patients continue to be followed on a yearly basis and the EORTC clinical study database now contains outcome data for over 210,000 cancer patients.
As well, EORTC contributes actively to the evolving eco-systems in oncology whether addressing methodological, scientific or regulatory challenges. EORTC remains also very active in education for clinical research-related science.
“This year we celebrate our past, but we also recognise the importance of continually evolving and adapting to meet future challenges and keep building on our distinguished record of scientific achievements.”
– Dr. Denis Lacombe, EORTC CEO.
On behalf of EORTC, we would like to express our sincere gratitude to all the people who support, collaborate, and believe in the mission of EORTC to improve the survival and quality of life of cancer patients.
Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types
30 May 2023
EORTC is supporting Clinical Trials Day on 20th May
19 May 2023
Studying long-term survivors of glioblastoma may pave the way to better treatment
10 May 2023
Three new EORTC clinical trials funded by the EU
24 Apr 2023
Important new results from EORTC to be presented at ESTRO 2023
14 Apr 2023
EORTC QLG proudly collaborates on the EUonQoL project
21 Mar 2023
HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer
22 Feb 2023
EORTC: Working towards “Closing the Care Gap”
2 Feb 2023
First international recommendations on the use of item libraries for patient-reported outcome measurement
31 Jan 2023
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
30 Jan 2023